Arihiro K, Inai K, Kurihara K, Takeda S, Kaneko M, Kuroi K, Toge T
Second Department of Pathology, Hiroshima University School of Medicine.
Jpn J Cancer Res. 1993 Jul;84(7):726-33. doi: 10.1111/j.1349-7006.1993.tb02036.x.
The integrin VLA-2 as a collagen receptor and VLA-5 as a fibronectin receptor were detected immunohistochemically in normal, benign tumor and carcinoma tissues of the breast. Both proteins were also detected by Western-blot analysis in some carcinoma cases. Epithelial and myoepithelial cells of both normal breast and benign tumor were in all cases immunoreactive for VLA-2 in the plasma membrane. Carcinoma cells in the invasive component were not immunoreactive for VLA-2 in 31 (46%) of 67 cases. Carcinoma cells in the intraductal components were negative for VLA-2 in only 4 (11%) of 36 cases, while 20 cases (56%) showed weak expression and 12 cases (33%) showed strong expression. Metastatic carcinoma cells in the lymph nodes of 6 cases showed no immunoreactivity except in one case, whereas, again with the exception of one case, the carcinoma cells in the primary tumors did show VLA-2 expression. With regard to VLA-5, there was no difference in its expression in the invasive components and the intraductal components. These findings suggest that the loss of VLA-2 plays a role in the invasion and metastasis of breast carcinoma.
采用免疫组织化学方法在乳腺正常组织、良性肿瘤组织及癌组织中检测整合素VLA - 2(作为胶原蛋白受体)和VLA - 5(作为纤连蛋白受体)。在一些癌组织病例中,通过蛋白质免疫印迹分析也检测到了这两种蛋白。正常乳腺和良性肿瘤的上皮细胞及肌上皮细胞在所有病例中,其质膜上的VLA - 2均呈免疫反应性。在67例病例中的31例(46%)浸润性成分中的癌细胞对VLA - 2无免疫反应性。在36例病例中,仅4例(11%)导管内成分中的癌细胞VLA - 2呈阴性,而20例(56%)表现为弱表达,12例(33%)表现为强表达。6例病例的淋巴结转移癌细胞除1例以外均无免疫反应性,而同样除1例以外,原发肿瘤中的癌细胞确实表现出VLA - 2表达。关于VLA - 5,其在浸润性成分和导管内成分中的表达无差异。这些发现提示VLA - 2的缺失在乳腺癌的侵袭和转移中起作用。